Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-06-11
1994-09-27
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514310, A61K 3147
Patent
active
053507576
ABSTRACT:
This invention relates to novel substituted 1,2,3,4-tetrahydroisoquinolines which are useful the treatment of vascular restenosis, various disorders of the central nervous system, in the regulation of female reproductive functions, in cognitive enhancement, in atherosclerosis and in treating excessive AVP secretory disorders. Novel intermediates useful in the preparation of the compounds are also disclosed. Methods of using the compounds and pharmaceutical compositions containing them are disclosed.
REFERENCES:
patent: 4812462 (1989-03-01), Blankley
patent: 5236934 (1993-08-01), VanAtten
M. K. VanAtten, et al., 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acids as Novel, Selective Inhibitors of Angiotensin II Binding to the AT.sub.2 Site. Aug. 22-27, 1993, 206th ACS Natl. Mtg., Chicago, Ill. Division of Med. Chem. Abstracts. Poster Presentation.
Am. J. Med., 76:4-12 (1984), W. P. Castelli, "Epidemiology of Coronary Heart Disease . . . ".
Hypertension 9:178-187 (1987), G. K. Owens, "Influence of Blood Pressure on Development of Aortic . . . ".
Science 245:186-188 (1989), J. S. Powell et al., "Inhibitors of Angiotensin-Converting . . . ".
Hypertension 18[Suppl II]:II65-II69 (1991), A. W. Clowes, "Heparin and Cilazapril Together Inhibit . . . ".
J. Card. Pharmacol., 16(4):S42-S49 (1990), J. W. Powell, "The Proliferative Response to Vascular Injury . . . ".
Hypertension, 18[Supp. II]:II55-II59 (1991), J. Clozel, "Inhibition of Converting Enzyme and Neointima . . . ".
Clin. Cardiol., 13:VII-43-48 (1990), A. V. Chobanian, "The Effects of ACE Inhibitors and Other . . . ".
J. Clin. Invest., 83:1419-1424 (1989), A Naftilan et al., "Induction of Platelet-derived Growth . . . ".
Biochem. Biophys. Res. Comm., 165(1):196-203 (1989), A. Chiu et al., "Identification of Angiotensin . . . ".
ibid., 172(3):1195-1202 (1990), A. Chiu et al., "[3H]DUP 753, a highly potent and specific . . . ".
Molecular Pharm., 38:370-377 (1990), D. Dudley et al., "Subclasses of Angiotensin II Binding Sites and . . . ".
Am. J. Pathology, 139(6):1291-1296 (1991), M. Prescott et al "Angiotensin-converting Enzyme Inhibitor . . . ".
Life Sciences, 49:PL-223-PL-228 (1991), R. Kauffman, "Losartan, a Nonpeptide Angiotensin . . . ".
J. Clin. Invest., 88:921-933 (1991) E. Grady et al., "Expression of AT2 Receptors in the Developing . . . ".
Biochem. Biophys. Res. Comm., 179(3):1361-1367 (1991), M. Viswanathan et al., "Changes in Expression . . . ".
Ann. Rev. Physiol., 49:413-435 (1987), M. I. Phillips, "Functions of Angiotensin in the Central . . . ".
Brain Res., 507:341-343 (1990), J. Barnes et al., "Angiotensin II inhibits acetylcholine . . . ".
Pharm. Biochem. & Behavior, 33:573-579 (1989), B. Costall, "The Effects of ACE Inhibitors Captopril . . . ".
Hypertension, 17:425 (1991), Schiavone et al.
Psychosomatic Medicine 35:143-154 (1973), D. Janowsky et al. "Correlations Between Mood, Weight, . . . ".
Biochemical Pharmacology, 42(4):715-719 (1991), P. Andrade-Gordon, "Role of Angiotensin . . . ".
Blankley Clifton J.
Hodges John C.
Klutchko Sylvester
Anderson Elizabeth M.
Barts Samuel
Dees Jos,e G.
Warner-Lambert & Company
LandOfFree
Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin II , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1265662